Text Size

A Study to Investigate the Effects of Rifampicin on the Pharmacokinetics of Aleglitazar in Healthy Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01679639
First received: September 1, 2012
Last updated: May 7, 2013
Last verified: May 2013
History of Changes
  Purpose

This open-label, fixed-sequence, three-period, single group study will evaluate the effects of rifampicin on the pharmacokinetics of aleglitazar in healthy volunteers. Volunteers will receive single doses of aleglitazar in all three periods and single doses of rifampicin in periods 1 and 2, and multiple doses in period 3. The anticipated time on study treatment is up to 14 weeks.


Condition Intervention Phase
Healthy Volunteer
 Drug: aleglitazar
Drug: rifampicin
 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: An Open-label, Fixed-sequence, Three-period, Single Group Study to Investigate the Effects of Rifampicin as an OATP1B1 Inhibitor and a CYP2C8 Inducer on the Pharmacokinetics of Aleglitazar in Healthy Subjects

Resource links provided by NLM:

Drug Information available for: Rifampin
U.S. FDA Resources

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Pharmacokinetics: Area under the plasma concentration time curve [ Time Frame: Period 1 and 2: Predose and days 1 to 5; Period 3: Days 5 to 12 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety: incidence of adverse events [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]

Enrollment: 24
Study Start Date: August 2012
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Aleglitazar Drug: aleglitazar
Single dose of aleglitazar in Periods 1, 2, 3
Drug: rifampicin
Single dose in Periods 1 and 2; multiple doses in Period 3

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers, aged 18 to 55 years inclusive at the time of screening
  • Body mass index (BMI) between 18.0 and 35.0 kg/m2 inclusive
  • Females must be surgically sterile or use two acceptable methods of contraception
  • Non-smoker or currently smoking less than five cigarettes/day and willing to abstain from smoking during the study

Exclusion Criteria:

  • Any clinically relevant abnormal laboratory test results at screening or on Day -1 of all periods, as judged by the Investigator
  • A history of clinically significant disorders (e.g., gastro-intestinal, cardiovascular, hepatic)
  • Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
  • An average alcohol intake of more than 14 units per week
  • Volunteers diagnosed, or suspected of having porphyria, and subjects with first degree relatives diagnosed, or suspected of having porphyria
  • Diagnosis of Gilberts Syndrome
  • A positive screen for drugs of abuse at screening or on admission to the clinical unit
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01679639

Locations
United Kingdom
Manchester, United Kingdom, M13 9WL
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01679639     History of Changes
Other Study ID Numbers: BP25561, 2012-002274-31
Study First Received: September 1, 2012
Last Updated: May 7, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Rifampin
Antibiotics, Antitubercular
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
 Antitubercular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on May 21, 2013